Maplight Therapeutics Inc (MPLT)

$26.50 -2.23 (-7.76%)
Market Cap 1.22B
Revenue (ttm) 0.00
Net Income (ttm) -161.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 535,000
Avg Vol 290,228
Day's Range N/A - N/A
Shares Out 42.61M
Stochastic %K 21%
Beta N/A
Analysts Strong Sell
Price Target $35.75

Company Profile

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's diseas...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 984 6300
Address:
800 Chesapeake Drive, Redwood City, United States
Duncan_
Duncan_ May. 19 at 2:57 PM
$MPLT Green on a red day is always nice
0 · Reply
Duncan_
Duncan_ May. 18 at 4:34 PM
$MPLT
0 · Reply
Duncan_
Duncan_ May. 12 at 7:42 PM
$MPLT https://www.nasdaq.com/market-activity/stocks/mplt/institutional-holdings?page=1&rows_per_page=10
1 · Reply
Duncan_
Duncan_ May. 12 at 1:45 PM
$MPLT anyone follow this novo holding company? do we know if they still own MPLT?
2 · Reply
DistributionEquity
DistributionEquity May. 8 at 8:06 PM
$MPLT Only 110 people watching. Its 45% owned by Sergei Brin's VC firm; It has 3 great looking p2 studies incubating; It is partnered with Googles' quantitative AI company; The share count is low; the cash balance is very high. Someone pinch me. I'm dreaming.
0 · Reply
CH_Expat
CH_Expat May. 8 at 6:38 PM
$MPLT Kill it for me and count me in under 20.
0 · Reply
CH_Expat
CH_Expat May. 1 at 6:35 PM
$MPLT 106 watchers is the most bullish indicator a biotech stock can possibly have. Your greedy friend never buys at ATH of course. Watchlist. Sexy markets indeed, Phase 1 looks excellent. Cc: @CDMO
1 · Reply
Duncan_
Duncan_ Apr. 29 at 7:25 PM
$MPLT kind of old but interesting:
0 · Reply
History101
History101 Apr. 23 at 2:09 AM
$MPLT 100 watching 4/22/2026
0 · Reply
nlrmandate
nlrmandate Apr. 22 at 11:28 PM
$VKTX anyone have any thoughts on $MPLT ? Working on drugs for Alzheimer's, Schizophrenia and ASD.....p1 results looked good and p2 for Schizophrenia and ASD to read out in q3 of this year (Alzheimer's p2 reads out mid-2027). Thinking about a starter position. Thanks in advance! Long VKTX and insanely
1 · Reply
Latest News on MPLT
MapLight Therapeutics reports Q1 EPS ($1.34), consensus ($1.12)

2026-05-14T20:45:03.000Z - 4 days ago

MapLight Therapeutics reports Q1 EPS ($1.34), consensus ($1.12)

MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:05 PM EDT - 4 days ago

MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 4 days ago

MapLight Therapeutics Earnings release: Q1 2026

MapLight Therapeutics Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 4 days ago

MapLight Therapeutics Quarterly report: Q1 2026

MapLight Therapeutics initiated with an Outperform at LifeSci Capital

2026-05-14T10:26:57.000Z - 5 days ago

MapLight Therapeutics initiated with an Outperform at LifeSci Capital

MapLight Therapeutics management to meet with Needham

2026-05-12T20:10:57.000Z - 6 days ago

MapLight Therapeutics management to meet with Needham

MapLight Therapeutics to Participate in Upcoming Investor Conferences

May 8, 2026, 7:00 AM EDT - 11 days ago

MapLight Therapeutics to Participate in Upcoming Investor Conferences

MapLight Therapeutics initiated with a Buy at H.C. Wainwright

2026-05-04T10:16:54.000Z - 15 days ago

MapLight Therapeutics initiated with a Buy at H.C. Wainwright

MapLight Therapeutics completes enrollment in ZEPHYR trial

2026-05-01T11:25:19.000Z - 18 days ago

MapLight Therapeutics completes enrollment in ZEPHYR trial

MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

May 1, 2026, 7:00 AM EDT - 18 days ago

MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

MapLight Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 20 days ago

MapLight Therapeutics Proxy statement: Proxy filing

MapLight Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 20 days ago

MapLight Therapeutics Proxy statement: Proxy filing

MapLight Therapeutics initiated with a Buy at Needham

2026-04-08T09:45:12.000Z - 5 weeks ago

MapLight Therapeutics initiated with a Buy at Needham

MapLight Therapeutics initiated with a Buy at TD Cowen

2026-04-07T09:41:31.000Z - 6 weeks ago

MapLight Therapeutics initiated with a Buy at TD Cowen

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 26, 2026, 7:00 AM EDT - 7 weeks ago

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MapLight Therapeutics Annual report: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 7 weeks ago

MapLight Therapeutics Annual report: Q4 2025

MapLight Therapeutics Earnings release: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 7 weeks ago

MapLight Therapeutics Earnings release: Q4 2025

MapLight Therapeutics Slides: Corporate presentation

Mar 26, 2026, 7:00 AM EDT - 7 weeks ago

MapLight Therapeutics Slides: Corporate presentation

Canaccord starts MapLight with Buy into schizophrenia data

2026-03-19T10:40:48.000Z - 2 months ago

Canaccord starts MapLight with Buy into schizophrenia data

MapLight Therapeutics initiated with a Buy at Canaccord

2026-03-19T09:20:13.000Z - 2 months ago

MapLight Therapeutics initiated with a Buy at Canaccord

MapLight Therapeutics expects topline results from ZEPHYR trial in Q3

2026-01-09T12:06:28.000Z - 4 months ago

MapLight Therapeutics expects topline results from ZEPHYR trial in Q3

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

Jan 9, 2026, 7:00 AM EST - 4 months ago

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

MapLight Therapeutics Slides: Corporate Presentation

Jan 9, 2026, 7:00 AM EST - 4 months ago

MapLight Therapeutics Slides: Corporate Presentation

MapLight Therapeutics receives fast track designation for ML-007C-MA for ADP

2026-01-05T12:11:46.000Z - 4 months ago

MapLight Therapeutics receives fast track designation for ML-007C-MA for ADP

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

Jan 5, 2026, 7:00 AM EST - 4 months ago

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

MapLight Therapeutics, SandboxAQ announce strategic collaboration

2025-12-16T12:05:49.000Z - 5 months ago

MapLight Therapeutics, SandboxAQ announce strategic collaboration

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

Dec 16, 2025, 7:00 AM EST - 5 months ago

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

MapLight Therapeutics reports Q3 EPS ($37.18) vs ($25.08) last year

2025-12-04T12:05:54.000Z - 5 months ago

MapLight Therapeutics reports Q3 EPS ($37.18) vs ($25.08) last year

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Dec 4, 2025, 7:00 AM EST - 5 months ago

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

MapLight Therapeutics Quarterly report: Q3 2025

Dec 4, 2025, 7:00 AM EST - 5 months ago

MapLight Therapeutics Quarterly report: Q3 2025

MapLight Therapeutics Earnings release: Q3 2025

Dec 4, 2025, 7:00 AM EST - 5 months ago

MapLight Therapeutics Earnings release: Q3 2025

MapLight Therapeutics Slides: Corporate Presentation

Dec 4, 2025, 7:00 AM EST - 5 months ago

MapLight Therapeutics Slides: Corporate Presentation

ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel

2025-12-03T16:05:09.000Z - 5 months ago

ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel

BMY

MapLight Therapeutics initiated with an Outperform at Leerink

2025-11-21T12:35:09.000Z - 6 months ago

MapLight Therapeutics initiated with an Outperform at Leerink

MapLight Therapeutics initiated with a Buy at Stifel

2025-11-21T10:10:27.000Z - 6 months ago

MapLight Therapeutics initiated with a Buy at Stifel

MapLight Therapeutics initiated with a Buy at Jefferies

2025-11-21T10:10:21.000Z - 6 months ago

MapLight Therapeutics initiated with a Buy at Jefferies

MapLight Therapeutics initiated with an Overweight at Morgan Stanley

2025-11-21T10:05:09.000Z - 6 months ago

MapLight Therapeutics initiated with an Overweight at Morgan Stanley

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 29, 2025, 9:06 AM EDT - 7 months ago

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut

Oct 27, 2025, 11:48 AM EDT - 7 months ago

MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut

MapLight Therapeutics Announces Pricing of Initial Public Offering

Oct 26, 2025, 5:30 PM EDT - 7 months ago

MapLight Therapeutics Announces Pricing of Initial Public Offering

MapLight Therapeutics Registration statement: Registration Filing

Oct 6, 2025, 2:00 AM EDT - 8 months ago

MapLight Therapeutics Registration statement: Registration Filing

MapLight Therapeutics IPO Registration Document (S-1)

Sep 19, 2025, 4:11 PM EDT - 8 months ago

MapLight Therapeutics IPO Registration Document (S-1)

MapLight Therapeutics Registration statement: Registration Filing

Sep 19, 2025, 7:00 AM EDT - 8 months ago

MapLight Therapeutics Registration statement: Registration Filing

CNS disorder biotech MapLight Therapeutics files for a $100 million IPO

Sep 19, 2025, 6:15 AM EDT - 8 months ago

CNS disorder biotech MapLight Therapeutics files for a $100 million IPO

Duncan_
Duncan_ May. 19 at 2:57 PM
$MPLT Green on a red day is always nice
0 · Reply
Duncan_
Duncan_ May. 18 at 4:34 PM
$MPLT
0 · Reply
Duncan_
Duncan_ May. 12 at 7:42 PM
$MPLT https://www.nasdaq.com/market-activity/stocks/mplt/institutional-holdings?page=1&rows_per_page=10
1 · Reply
Duncan_
Duncan_ May. 12 at 1:45 PM
$MPLT anyone follow this novo holding company? do we know if they still own MPLT?
2 · Reply
DistributionEquity
DistributionEquity May. 8 at 8:06 PM
$MPLT Only 110 people watching. Its 45% owned by Sergei Brin's VC firm; It has 3 great looking p2 studies incubating; It is partnered with Googles' quantitative AI company; The share count is low; the cash balance is very high. Someone pinch me. I'm dreaming.
0 · Reply
CH_Expat
CH_Expat May. 8 at 6:38 PM
$MPLT Kill it for me and count me in under 20.
0 · Reply
CH_Expat
CH_Expat May. 1 at 6:35 PM
$MPLT 106 watchers is the most bullish indicator a biotech stock can possibly have. Your greedy friend never buys at ATH of course. Watchlist. Sexy markets indeed, Phase 1 looks excellent. Cc: @CDMO
1 · Reply
Duncan_
Duncan_ Apr. 29 at 7:25 PM
$MPLT kind of old but interesting:
0 · Reply
History101
History101 Apr. 23 at 2:09 AM
$MPLT 100 watching 4/22/2026
0 · Reply
nlrmandate
nlrmandate Apr. 22 at 11:28 PM
$VKTX anyone have any thoughts on $MPLT ? Working on drugs for Alzheimer's, Schizophrenia and ASD.....p1 results looked good and p2 for Schizophrenia and ASD to read out in q3 of this year (Alzheimer's p2 reads out mid-2027). Thinking about a starter position. Thanks in advance! Long VKTX and insanely
1 · Reply
LewisDaKat
LewisDaKat Apr. 22 at 7:00 PM
$MPLT What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data https://marketwirenews.com/stock/mplt/news/what-a-1-insider-sale-of-mplt-stock-signals-ahead-of-5992050166974582.html?utm_source=stocktwits
0 · Reply
Hopipaytrader
Hopipaytrader Apr. 22 at 5:14 PM
$MPLT can we touch $34 for me thanks
0 · Reply
Dirtdemon75
Dirtdemon75 Apr. 22 at 2:26 PM
$MPLT
0 · Reply
Doozio
Doozio Apr. 10 at 12:27 AM
$MPLT YO wanna be a part of $ITT …….
0 · Reply
BiotechButterflies
BiotechButterflies Apr. 9 at 7:58 PM
$MPLT ... the rally ahead of the two Ph2 topline readouts in Q3? Two shots on goal reading out in a narrow time.... thrilling stuff....
0 · Reply
TrustButVerifi
TrustButVerifi Apr. 9 at 6:47 PM
$MPLT $VKTX $WULF
0 · Reply
TrustButVerifi
TrustButVerifi Apr. 9 at 6:37 PM
$MPLT Looks like a BO leak here!
0 · Reply
TrustButVerifi
TrustButVerifi Apr. 9 at 6:36 PM
$VKTX $MPLT $WULF
0 · Reply
History101
History101 Apr. 9 at 6:24 PM
$MPLT only 81 watching 4/9/2026
1 · Reply
notreload_ai
notreload_ai Apr. 8 at 2:14 PM
Stifel & Needham back $INBX & $MPLT : promising cancer & brain drugs, strong safety, big market potential. https://notreload.xyz/xy/wall-street-goes-bullish-on-two-biotech-stocks-inbx-and-mplt/
0 · Reply
twincam
twincam Apr. 7 at 12:59 PM
$MPLT With patent cliffs looming, $MPLT looks like prime M&A bait. Circuit-targeted CNS drugs + Q3 ’26 readouts in schizo & autism. Ready to take on BMS? Watch $JNJ, $SNY, $LLY. $MPLT”
0 · Reply
Quantumup
Quantumup Apr. 7 at 11:53 AM
TD Cowen🏁 $MPLT at a Buy rating. $BMY $NBIX BTAI VNDA ABBV TEVA AXSM TD Cowen said in its initiation report: Maplight is advancing candidates for the treatment of CNS and neuropsych conditions. Lead asset ML-007C MA looks to improve upon Cobenfy's profile in the treatment of schizophrenia with Ph. Il data set for Q3. A Ph. Il study in Alzheimer's psychosis would expand the therapy's opportunity. ML-004 is in a Ph. Il study for ASD (Q3:26 data). We see shares as undervalued for schizophrenia alone. Buy.
0 · Reply